ArticleJournal of neurology2025
Refractory focal epilepsy evolving into a Lennox-Gastaut syndrome-like.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with focal epilepsy may over time experience a significantly unfavorable progression, developing an electroclinical profile that meets some or all criteria for Lennox-Gastaut syndrome (LGS). This study aimed to describe the electroclinical characteristics of these patients, whom we referred to as patients with LGS-like, and to determine their common and distinguishing features compared to classical LGS.
methodsWe retrospectively examined 2,130 adult-patients who underwent video-EEG monitoring from 2002 to 2024. LGS-like was defined as focal epilepsy with over the disease's course: (1) a clinically unfavorable progression, (2) the development of generalized paroxysmal fast activity (GPFA) on EEG, and (3) another LGS criteria: tonic/atonic seizures, and/or cognitive and/or behavioral regression, and/or diffuse slow spike-and-wave (SSW) activity. Patients with LGS-like were classified into full or partial spectrum based on whether or not they met all the criteria for LGS.
resultsThirty-four patients (1.6%) met the criteria for LGS-like syndrome (median age at seizure onset: 10.5 ± 6.9 years [range 1-33]; median epilepsy duration: 15.5 ± 11 years [range 1-45]). Among them, 21 patients had tonic seizures, three had atonic seizures, and one exhibited both. Eight patients showed cognitive and/or behavioral regression, while 29 patients displayed diffuse SSW patterns. Seven patients (20.5%) fulfilled the criteria for full-spectrum LGS. Compared with classical LGS, patients with LGS-like showed distinct features: (1) later seizure onset, (2) lower rate of cognitive regression (23.5%), (3) predominantly asymmetric tonic seizures and focal seizures during GPFA (62%), (4) frequent asymmetric GPFA (50%) and GPFA during wakefulness (53%), (5) high rate of SSW at adulthood (85%), though mostly asymptomatic, (6) normal EEG background activity (91%), and (7) favorable outcomes in 69% of cases. The only distinguishing factor between full-spectrum and partial-spectrum LGS was disease severity at the time of video-EEG: all full-spectrum LGS patients (100%) experienced daily seizures, compared with 55.6% of partial-spectrum patients (p = 0.0036). The similar favorable outcome in both groups (71% vs. 68%, p = 0.7) highlight the potential reversibility of the processes underlying LGS-like, regardless of the number of LGS diagnostic criteria met.
conclusionsThe evolution from focal epilepsy to a syndrome that met some or all criteria for LGS supports the existence of a pathological continuum between the underlying epileptic networks. Early identification of such patients may enable timely therapeutic adaptation and help prevent unfavorable outcomes.
Indexed as
Identifiers
41249689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.